ATOPİK DERMATİTTE OMALİZUMAB ETKİNLİĞİNİN RETROSPEKTİF DEĞERLENDİRİLMESİ

Giriş: Atopik Dermatit (AD), sık görülen, tekrarlayıcı, kronik inflamatuar bir deri hastalığıdır ve hastalığın şiddeti serum immünoglobin E (IgE) seviyesi ile güçlü bir korelasyon gösterir. Mevcut tedaviler arasında sıklıkla immünsüpresif ajanlar yer alır ancak bu tedaviler kısa ve uzun dönem yan etkilere neden olabilmektedir. Bu çalışmanın amacı, AD'li hastalarda omalizumabın etkinliğini araştırmaktır. Gereç ve Yöntem: Dirençli AD tanısı alan 25 hastada omalizumabın etkinliği ve yan etkileri retrospektif olarak incelendi. Omalizumab 2 haftada bir 300 mg subkutan olarak olarak uygulandı. Hastalarda, başlangıçta ve tedavinin 12. haftasında kaydedilen serum IgE düzeyleri ve Atopik Dermatitin Şiddet Skoru (SCORAD) değerleri değerlendirildi. Hastalar yan etkiler açısından yakından takibe alındı. Bulgular: AD için omalizumab alan 25 hastanın yaşları 12-54 arasındaydı ve hastaların 15’i kadındı. Tedavinin başlangıcında ortalama serum IgE seviyeleri 1428IU/Ml iken ve 12. haftada 262IU/Ml'ye düştü. Ortalama SCORAD puanı 12 haftada 58'den 29,8'e geriledi. On sekiz hasta omalizumab tedavisine mükemmel klinik yanıt verirken 7 hastada tatmin edici klinik yanıt saptandı. Omalizumab tedavisi sırasında hastalarda herhangi bir yan etki gözlenmedi. Sonuç: Omalizumab tedavisi dirençli AD hastaları için güvenli ve etkili bir tedavi seçeneği olarak değerlendirildi.

RERTOSPECTIVE ANALYSIS OF THE EFFICACY OF OMALIZUMAB IN ATOPIC DERMATITIS

Introduction: Atopic Dermatitis (AD) is a frequent, relapsing, chronic inflammatory skin condition that shows a strong correlation between serum immunoglobin E (IgE) levels. Curren t therapies are often immunosuppressant and may be associated with both short and long-term side effects. The aim of the study is to investigate the efficacy of omalizumab in patients with AD. Material and Method: The efficacy and side effects of omalizumab were evaluated retrospectively in 25 patients who were diagnosed with resistant AD. Omalizumab was administered 300 mg subcutaneously per 2 weeks. Inpatients, the values of serum IgE levels and Severity Scoring of AtopicDermatitis (SCORAD) recorded at the beginning and at the 12th week of the treatment were evaluated. Patients were followed closely for side effects. Results: Theages of 25 patients receiving omalizumab for AD were between 12-54, and 15 of the patients were female. The mean levels of serum IgE were 1428IU/Ml at the beginning of the therapy and reduced to 262IU/Ml at 12 th week. The mean SCORAD points reduced from 58 to 29,8 in 12 week. Eighteen patients showed an excellent clinical respond to omalizumab therapy, and 7 patient showed satisfying clinical respond. No side effects were observed during treatment. Conclusion: Omalizumab can be considered as a safe and effective therapy for AD.

PDF

___

1. Weidinger S, Novak N: Atopic dermatitis. Lancet 2016; 387(10023): 1109-22.
2. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70(2): 338-51.
3. Katayama I, Kohno Y, Akiyama K, Aihara M, Kondo N, Saeki H et al. Japanese Guideline for Atopic Dermatitis 2014. Allergol Int 2014; 63(3): 377-98.
4. Ertam İ, Su Ö, Alper S, Sarıcaoğlu H, Karadağ AS, Dermirsoy EO et al. Türkiye Atopik Dermatit Tanı ve Tedavi Klavuzu2018.Türkderm 2018; 52(1): 6-23
5. Ellis CN, Mancini AJ, Paller AS, Simpson EL, Eichenfield LF. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg 2012; 31(3): 18-22.
6. Boguniewicz M, Leung DY.Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242(1): 233-46.
7. Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001; 44(1): 13-6.
8. Vichyanond P. Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol 2011; 29(3): 209–19.
9. Busse W, Corren J, Lanier BQ, McAlary M, Folwer-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-9.
10. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ.Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54(1): 68–72.
11. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53(2): 338–40.
12. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006; 55(1): 168–17.
13. Romano C, Sellitto A, De Fanis U, Balestrieri A, Savoia A, Abbadessa S et al. Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. Clin Drug Investing 2015; 35(3): 159–68.
14. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54(1): 68-72.
15. Sirufo MM, De Martinis M, Ginaldi L.Omalizumab an effective and safe alternative therapy in severe refractory atopic dermatitis: A case report. Medicine (Baltimore) 2018; 97(24): 10897.
16. Wang HH, Li YC, Huang YC.Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and metaanalysis. J Allergy Clin Immunol 2016; 138(6): 1719-22.
17. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does notimprove the clinical course – a randomized, placebocontrolled and double blind pilot study. Dtsch Dermatol Ges 2010; 8(12): 990–9.
18. Iyengar SR, Hoyte EG, Loza A,Bonaccorso S, Chiang D,Umetsu DT et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013; 162(1): 89–93.
19. Pozo MER. Omalizumab (an anti-IgE antibody) in the Treatment of Severe Atopic Eczema. J Investig Allergol Clin Immunol 2011; 21(5): 416–7.
20. Caruso C, Gaeta F, Valluzzi RL. Omalizumab efficacy in a girl with atopic eczema. Allergy 2010; 65(2):278–9.
21. Incorvaia C, Pravettoni C, Mauro M,Yacoub MR, Tarantini, F, Riario SG. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 2008; 69(2): 78–80.
22. Park SY, Choi MR, Na JI, Sang-WoongY, Park KJ, Huh CH. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010; 22(3): 349–52.
23. Orman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FceRI. Cutis 2007; 80(1): 38–40.
24. Amrol DM. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2009;38(5): 554–8.
25. Holm JG, Agner T, Sand C, Thomsen SF.Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol 2017;56(1):18-26.
26. Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. Hindawi Publishing Corporation ISRN Allergy 2014; 2:354250.
27. Hotze M, Baurecht H, Rodríguez E,Chapman-Rothe N, Ollert M, Fölster HR et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014; 69(1):132–5.
28. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB.Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29(5):530-7.
29. Leynadier F, Doudou O, Gaouar H,Gros V, Bourdeix I, Guyomarch CL et al. Effect of omalizumab in health care workers with occupational latex allergy.J Allergy Clin Immunol 2004;113(2):360-1.
30. Leung DY, Sampson HA, Yunginger JW,BurksAW, Schneider LC, Wortel CH et al. Effect of anti-IgE therapy in patients with peanut allergy.N Engl J Med 2003;348(11):986-93.
31. Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchanian V et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol 2016; 96(1): 72–6.
32. Deleanu D, Nedelea I.Biological therapies for atopic dermatitis: An update. Exp Ther Med. 2019;17(2):1061-7
33. Velling P, Skowasch D, Pabst S,Jansen E, Tuleta I, Grohé C. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res 2011; 16(9): 407.
34. Lacombe Barrios J, Bégin P, Paradis L,Hatami A, Paradis J, Roches AD. Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol 2013;69(5):832-4.